Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Life expectancy for multiple myeloma patients has increased since the introduction of autologous stem cell transplantation and novel agents. While positive, longer life expectancy also relates to greater risk of second primary malignancies. This summary reviews current information about possible host-, disease-, and treatment-related risk factors for the development of second primary malignancies. Provided are practical recommendations to assist physicians.
P. Musto K. C. Anderson M. Attal P. G. Richardson A. Badros J. Hou R. Comenzo J. Du B. G. M. Durie J. San Miguel H. Einsele W. M. Chen L. Garderet G. Pietrantuono J. Hillengass R. A. Kyle P. Moreau J. J. Lahuerta O. Landgren H. Ludwig A. Larocca A. Mahindra M. Cavo A. Mazumder P. L. McCarthy A. Nouel S. V. Rajkumar A. Reiman E. R. Serra O. Sezer E. Terpos I. Turesson S. Usmani B. M. Weiss A. Palumbo on behalf of the International Myeloma Working Group
Learn more at: